Iowa is currently home to 796 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Iowa City, Des Moines, Sioux City and Cedar Rapids. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Otoferlin Gene-mediated Hearing Loss Natural History Study
NCT05572073
Recruiting
This is a retrospective and prospective longitudinal study in participants with Otoferlin Gene-Mediated Hearing Loss.
Gender:
ALL
Ages:
44 years and below
Trial Updated:
10/21/2024
Locations: University of Iowa, Iowa City, Iowa
Conditions: Sensorineural Hearing Loss, Bilateral
Register for Updates
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828
Recruiting
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer sur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Mary Greeley Medical Center, Ames, Iowa
Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Register for Updates
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
NCT05863351
Recruiting
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Mary Greeley Medical Center, Ames, Iowa
Conditions: Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT03681561
Recruiting
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Hodgkin Lymphoma
Register for Updates
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
NCT05119556
Recruiting
The purpose of this study is to compare the efficacy and safety of a real time video telehealth pulmonary rehabilitation intervention with standard of care in patients hospitalized for an exacerbation of chronic obstructive pulmonary disease (COPD) to determine the impact on hospital readmissions and respiratory morbidity, and to investigate the cost-effectiveness of the intervention.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
10/17/2024
Locations: University of Iowa, Iowa City, Iowa
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19
NCT06311435
Recruiting
The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2024
Locations: University of Iowa, Iowa City, Iowa
Conditions: Long COVID
Register for Updates
TSC Biosample Repository and Natural History Database
NCT05676099
Recruiting
The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document the impact of the disease on a person's health over his or her lifetime. This data may be collected retrospectively or prospectively.
Gender:
ALL
Ages:
All
Trial Updated:
10/15/2024
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Tuberous Sclerosis, Lymphangioleiomyomatosis
Register for Updates
The PREDICTOR Study: Assessing Diagnostic Predictors of Airway Collapse in Patients With Obstructive Sleep Apnea
NCT05428839
Recruiting
This study is an exploratory, multicenter study of up to 300 subjects diagnosed with obstructive sleep apnea who are being evaluated for airway surgery. Subjects will undergo standard evaluation for airway surgery as part of standard of care. In addition to the standard airway assessment, a simple, non-invasive measurement of the width of the inside of each subjects mouth will be performed. This measurement takes 2-3 minutes to perform.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Mason City Clinic, Mason City, Iowa
Conditions: Sleep Apnea, Obstructive
Register for Updates
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies ha... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
10/14/2024
Locations: Wolfe Eye Clinic, West Des Moines, Iowa
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Register for Updates
Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy
NCT01429389
Recruiting
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: University of Iowa Health Care, Iowa City, Iowa
Conditions: Down Syndrome, Fetal Aneuploidy
Register for Updates
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
NCT03942653
Recruiting
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Salivary Gland Carcinoma
Register for Updates
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT04851613
Recruiting
Study LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy, and/or CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: University of Iowa, Iowa City, Iowa
Conditions: Breast Cancer
Register for Updates